U.S. Markets close in 4 hrs 40 mins

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.11-0.34 (-2.97%)
As of 11:20AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.45
Bid11.11 x 800
Ask11.17 x 800
Day's Range11.08 - 11.43
52 Week Range10.65 - 24.70
Avg. Volume431,653
Market Cap759.169M
Beta (5Y Monthly)-0.07
PE Ratio (TTM)N/A
EPS (TTM)-2.83
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
  • GlobeNewswire

    Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

    HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hou

  • GlobeNewswire

    Kiniksa Announces Launch of ARCALYST Named Patient Program

    - Named Patient Program supports patient access to ARCALYST® (rilonacept) in countries where ARCALYST is not currently commercially available - HAMILTON, Bermuda, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant

  • Zacks

    Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

    Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 11.59% and 200.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?